These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 30738502)

  • 1. Re: Disregarding the impact of nicotine on the developing brain when evaluating costs and benefits of noncombustible nicotine products.
    Abrams DB; Glasser AM; Villanti AC; Pearson JL; Rose S; Niaura RS
    Prev Med; 2019 Mar; 120():158-159. PubMed ID: 30738502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing nicotine without smoke to save lives now: Evidence for harm minimization.
    Abrams DB; Glasser AM; Villanti AC; Pearson JL; Rose S; Niaura RS
    Prev Med; 2018 Dec; 117():88-97. PubMed ID: 29944902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disregarding the impact of nicotine on the developing brain when evaluating costs and benefits of noncombustible nicotine products.
    Flannery JS
    Prev Med; 2019 Mar; 120():157. PubMed ID: 30738501
    [No Abstract]   [Full Text] [Related]  

  • 4. Urinary Leukotriene E
    Makena P; Liu G; Chen P; Yates CR; Prasad GL
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2095-2105. PubMed ID: 31558507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tobacco harm reduction: the need for new products that can compete with cigarettes.
    Fagerström KO; Bridgman K
    Addict Behav; 2014 Mar; 39(3):507-11. PubMed ID: 24290207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reducing the nicotine content of combusted tobacco products sold in New Zealand.
    Donny EC; Walker N; Hatsukami D; Bullen C
    Tob Control; 2017 Mar; 26(e1):e37-e42. PubMed ID: 27672126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deficiencies in public understanding about tobacco harm reduction: results from a United States national survey.
    Kiviniemi MT; Kozlowski LT
    Harm Reduct J; 2015 Jul; 12():21. PubMed ID: 26135116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Australian urban Indigenous smokers' perspectives on nicotine products and tobacco harm reduction.
    Yuke K; Ford P; Foley W; Mutch A; Fitzgerald L; Gartner C
    Drug Alcohol Rev; 2018 Jan; 37(1):87-96. PubMed ID: 28493405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toward a comprehensive policy on nicotine delivery products and harm reduction.
    Solyst J
    Food Drug Law J; 2012; 67(4):393-404, i. PubMed ID: 24640613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing modified risk tobacco and nicotine products: Description of the scientific framework and assessment of a closed modular electronic cigarette.
    Murphy J; Gaca M; Lowe F; Minet E; Breheny D; Prasad K; Camacho O; Fearon IM; Liu C; Wright C; McAdam K; Proctor C
    Regul Toxicol Pharmacol; 2017 Nov; 90():342-357. PubMed ID: 28954704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. E-cigarettes: a need to broaden the debate.
    Latif E; Nair M
    Int J Tuberc Lung Dis; 2016 Nov; 20(11):1430-1435. PubMed ID: 27776582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smokers' risk perceptions and misperceptions of cigarettes, e-cigarettes and nicotine replacement therapies.
    King B; Ndoen E; Borland R
    Drug Alcohol Rev; 2018 Sep; 37(6):810-817. PubMed ID: 29920819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of smokeless tobacco product marketing and use on population harm from tobacco use policy perspective for tobacco-risk reduction.
    Kozlowski LT
    Am J Prev Med; 2007 Dec; 33(6 Suppl):S379-86. PubMed ID: 18021913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of product definitions in US e-cigarette laws and regulations.
    Lempert LK; Grana R; Glantz SA
    Tob Control; 2016 Apr; 25(e1):e44-51. PubMed ID: 25512432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Tobacco Product Use Patterns Among U.S. Youth, 1999-2014.
    El-Toukhy S; Sabado M; Choi K
    Nicotine Tob Res; 2018 May; 20(6):690-697. PubMed ID: 28582567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential impact of vaporized nicotine products on vulnerable subpopulations.
    Gartner C
    Addiction; 2017 Jan; 112(1):18-19. PubMed ID: 27154404
    [No Abstract]   [Full Text] [Related]  

  • 17. Nicotine Delivery to the Aerosol of a Heat-Not-Burn Tobacco Product: Comparison With a Tobacco Cigarette and E-Cigarettes.
    Farsalinos KE; Yannovits N; Sarri T; Voudris V; Poulas K
    Nicotine Tob Res; 2018 Jul; 20(8):1004-1009. PubMed ID: 28637344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced nicotine content cigarettes in smokers of low socioeconomic status: study protocol for a randomized control trial.
    Krebs NM; Allen SI; Veldheer S; Martinez DJ; Horn K; Livelsberger C; Modesto J; Kuprewicz R; Wilhelm A; Hrabovsky S; Kazi A; Fazzi A; Liao J; Zhu J; Wasserman E; Reilly SM; Reinhart L; Trushin N; Moyer RE; Bascom R; Foulds J; Richie JP; Muscat JE
    Trials; 2017 Jul; 18(1):300. PubMed ID: 28673312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA's regulatory shift on tobacco control.
    Yang YT
    Prev Med; 2018 Aug; 113():153-155. PubMed ID: 29866276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotine and health.
    Drug Ther Bull; 2014 Jul; 52(7):78-81. PubMed ID: 25012148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.